Copyright
©The Author(s) 2015.
World J Gastroenterol. Feb 21, 2015; 21(7): 2096-2101
Published online Feb 21, 2015. doi: 10.3748/wjg.v21.i7.2096
Published online Feb 21, 2015. doi: 10.3748/wjg.v21.i7.2096
Table 1 Patient characteristics
| Characteristics | Patients (n) |
| Median age (range) (yr) | 60 (39-72) |
| Sex | |
| Male | 6 |
| Female | 7 |
| ECOG performance status | |
| 0 | 3 |
| 1 | 8 |
| 2 | 2 |
| Median CA 19-9 level (range) (ng/mL) | 73 (2-4472) |
| Previous chemotherapy | |
| Intravenous gemcitabine oxaliplatin | 13 |
| Intra-arterial gemcitabine oxaliplatin | 5 |
| Tumor limiting the liver | |
| Yes | 4 |
| No | 9 |
- Citation: Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101
- URL: https://www.wjgnet.com/1007-9327/full/v21/i7/2096.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i7.2096